Trial Profile
A phase I, three part study, in healthy subjects to assess the safety, tolerability and pharmacokinetics of single and multiple doses of DSP-2230, and the effect of the administration in the fed and fasted states on the pharmacokinetics of DSP-2230
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs DSP 2230 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Sunovion Pharmaceuticals
- 15 Jan 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 28 May 2012 New trial record